Blue Owl Capital Holdings LP Takes $26.16 Million Position in Maplight Therapeutics, Inc. $MPLT

Key Points

• Blue Owl Capital Holdings acquired 729,929 Maplight Therapeutics shares worth approximately $26.16 million, making MPLT about 3.9% of its portfolio and representing roughly 1.71% of the company.
• Institutional interest increased as several funds initiated positions, while insider activity was mixed: Director Troy Cox bought 15,620 shares, and James Woodruff Lillie sold 22,082 shares under a pre-arranged Rule 10b5-1 plan.
• Maplight reported a quarterly loss of $1.32 per share, beating estimates for a $1.40 loss. Analysts maintain a “Moderate Buy” consensus with an average price target of $29.67, despite recent rating and target-price reductions from some firms.

Blue Owl Capital Holdings LP acquired a new position in Maplight Therapeutics, Inc. (NASDAQ:MPLT - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 729,929 shares of the company's stock, valued at approximately $26,161,000. Maplight Therapeutics comprises about 3.9% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 6th largest position. Blue Owl Capital Holdings LP owned about 1.71% of Maplight Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Strs Ohio purchased a new stake in shares of Maplight Therapeutics during the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Maplight Therapeutics during the 4th quarter valued at about $70,000. New York State Common Retirement Fund purchased a new position in Maplight Therapeutics in the 4th quarter worth $93,000. MetLife Investment Management LLC bought a new stake in Maplight Therapeutics in the fourth quarter valued at approximately $172,000. Finally, Deutsche Bank AG bought a new position in shares of Maplight Therapeutics during the second quarter valued at about $370,000.

Insider Buying and Selling at Maplight Therapeutics

In other Maplight Therapeutics news, Director Troy Cox bought 15,620 shares of Maplight Therapeutics stock in a transaction that occurred on Tuesday, July 28th. The stock was purchased at an average price of $9.52 per share, with a total value of $148,702.40. Following the completion of the acquisition, the director directly owned 15,620 shares in the company, valued at approximately $148,702.40. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider James Woodruff Lillie sold 22,082 shares of the business's stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $12.54, for a total value of $276,908.28. Following the completion of the transaction, the insider directly owned 202,380 shares of the company's stock, valued at approximately $2,537,845.20. This trade represents a 9.84% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.80% of the company's stock.

Maplight Therapeutics Stock Performance

Shares of MPLT opened at $11.23 on Friday. Maplight Therapeutics, Inc. has a fifty-two week low of $9.10 and a fifty-two week high of $40.43. The company has a 50 day moving average price of $25.90 and a 200-day moving average price of $24.34. The stock has a market capitalization of $520.85 million and a PE ratio of -0.27.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.32) EPS for the quarter, topping analysts' consensus estimates of ($1.40) by $0.08. Equities research analysts forecast that Maplight Therapeutics, Inc. will post -5.12 EPS for the current year.

Analyst Upgrades and Downgrades

MPLT has been the topic of several research reports. Needham & Company LLC lifted their price objective on Maplight Therapeutics from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Raymond James Financial set a $31.00 price objective on Maplight Therapeutics in a research report on Friday, August 14th. UBS Group cut Maplight Therapeutics from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $52.00 to $13.00 in a research report on Monday, August 10th. Wolfe Research reissued an "outperform" rating and issued a $30.00 price target on shares of Maplight Therapeutics in a report on Monday, July 27th. Finally, Morgan Stanley reaffirmed an "equal weight" rating and set a $21.00 price objective (down from $34.00) on shares of Maplight Therapeutics in a report on Tuesday, July 28th. Four investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $29.67.

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

Want to see what other hedge funds are holding MPLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maplight Therapeutics, Inc. (NASDAQ:MPLT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source